Negotiating a licensing or partnership deal with a major pharmaceutical company is one of the most consequential business events a small biotech or pharma company will face. The power imbalance is significant. The large pharma has a business development team with dozens of completed deals, a law firm on retainer, and precedent language it uses repeatedly. The small company may be negotiating its first or second major deal with limited legal resources and significant time pressure. But the power imbalance does not mean all terms are non-negotiable, and it does not mean you cannot protect your interests if you approach negotiations strategically.

At Lopes Law LLC, Anthony Lopes, Esq. brings BigLaw experience from Duane Morris LLP and hands-on pharmaceutical contract experience from Merck’s clinical trials launch department to every client engagement. We advise small biotech and pharma clients on how to prepare for these negotiations, identify leverage, and protect the provisions that matter most for long-term value realization.

What Leverage Does a Small Biotech Have Against Big Pharma?

The most important leverage is competitive interest. If more than one large pharmaceutical company is interested in licensing your asset, you have real negotiating power. Never enter exclusive discussions prematurely. The moment you sign an exclusivity period with one party, your leverage with all others disappears for that period. Build competitive tension by keeping multiple conversations open and allowing interested parties to know (without violating confidentiality) that discussions are ongoing.

Strong clinical data is the most durable leverage. A compound with Phase 2 proof-of-concept data in a validated indication with a clear regulatory path commands substantially better terms than a pre-clinical candidate. Before entering major licensing negotiations, ensure your data package is as complete and well-organized as possible. A well-documented, organized data room reduces the large pharma’s due diligence burden and risk perception, which improves the deal terms you can achieve.

Patent portfolio strength matters. A compound protected by multiple issued patents with strong claims and clear freedom to operate for the target indication gives the large pharma confidence in the exclusivity of what they are licensing. Weak or narrow patent protection creates negotiating pressure on the licensor. Before entering major negotiations, have your IP counsel assess the patent portfolio and identify any vulnerabilities that should be addressed first.

Understanding the large pharma’s internal timeline can also create leverage. Many large pharmaceutical companies operate on fiscal year budgets with specific windows for business development approvals. Year-end budget pressures can create favorable conditions for licensors when the large pharma’s business development team needs to close a deal before the fiscal year ends. At Lopes Law LLC, we advise small biotech clients to research the counterparty’s fiscal calendar and, where possible, time their negotiations to coincide with these decision windows. A deal that closes in Q4 may attract a larger upfront payment than the same deal negotiated in Q1 when the new fiscal year budget is still being allocated.

What Contract Provisions Should Small Pharma Fight For?

Net sales definition is one of the highest-value negotiating items because it determines the actual royalty base. Large pharma standard forms often include very broad permitted deductions from gross sales: government rebates, managed care chargebacks, prompt payment discounts, bad debt reserves, and distribution fees. Stacking all permitted deductions can reduce net sales by 20 to 40% from gross sales, materially reducing the royalty you receive. Push back on each deduction category and negotiate caps on total deductions.

Diligence obligations with real consequences are essential. The standard “commercially reasonable efforts” provision is a licensor’s weakest protection. Require instead: specific minimum annual development spend by program stage (for example, minimum of 5 million dollars annually in Phase 2 development), specific milestone deadlines with reversion of rights as the consequence of missing them, and after approval, minimum first-year promotional spend and sales force dedication requirements. Without measurable diligence obligations, the large pharma can simply deprioritize your compound if internal priorities shift.

Reversion rights on termination are the licensor’s ultimate protection. Most pharma license agreements permit the licensee to terminate for convenience with advance notice. When that happens, the licensor should receive back: all licensed IP and patent rights, all regulatory filings and correspondence (including the IND), all clinical data and study reports, all manufacturing know-how related to the compound, and all sublicensee arrangements that the licensor wants to preserve. At Lopes Law LLC, we negotiate specific reversion packages that maximize the licensor’s ability to relicense the asset after termination.

What Mistakes Do Small Pharma Companies Make in Big Pharma Negotiations?

Signing the term sheet without legal review is the most common and costliest mistake. Term sheets are routinely presented as “just a preliminary document” or “non-binding.” But most term sheets include provisions that are actually binding: exclusivity clauses (which prevent the small company from talking to other potential partners for a specified period), governing law and dispute resolution clauses, and no-shop provisions. These binding provisions can be highly consequential and should be reviewed before signature.

Sharing data before the NDA is fully negotiated reduces your leverage significantly. Once the large pharma’s scientific team has reviewed your compound data, their interest level is no longer purely hypothetical. Many small companies, eager to demonstrate confidence in their compound, share detailed data before all NDA provisions are agreed upon. Do not do this. Negotiate the NDA completely, including residuals clauses and IP ownership provisions, before sharing anything beyond publicly available information.

Consider a scenario from our practice: a small biotech signed a 90-day exclusivity period with a large pharma after receiving strong interest signals. During the 90-day period, the large pharma’s due diligence team discovered a competitor compound in their own internal pipeline that targeted the same indication. The large pharma decided not to proceed with the licensing deal. During those 90 days, the small biotech had turned away two other interested parties who had reached out. By the time the exclusivity expired, the window of peak acquisition interest had closed. At Lopes Law LLC, we now advise clients to keep exclusivity periods to 30 to 45 days maximum and to require specific due diligence milestones from the large pharma during the period.

How Should Small Pharma Approach Sublicensing and Third-Party Partnerships?

If the large pharma intends to sublicense your compound to regional partners or territory-specific partners, the licensor should receive a meaningful share of sublicensing revenue: typically 15 to 30% for pre-clinical to Phase 2 stage assets. The sublicensing revenue share compensates the licensor for the value being passed downstream and prevents the large pharma from extracting large sublicensing payments while paying only royalties on their own direct sales.

The license agreement should require the licensee to notify the licensor when sublicenses are granted, to flow down diligence obligations to sublicensees, and to ensure the licensor’s royalty rights survive as third-party beneficiary rights against sublicensees if the main license is terminated. Without this structure, a termination of the main license could eliminate royalty flows from active sublicensees who are actually commercializing the product.

At Lopes Law LLC, we review all sublicensing provisions with attention to the long-term royalty and reversion implications. The economics of a sublicensing scenario often differ significantly from the economics modeled at the time the main license is signed, and the agreement must account for this variability. For deals involving assets with global commercial potential, sublicensing revenue can represent 30 to 50% of the total economic value of the license over its lifetime.

How Should Small Pharma Protect IP During Early Discussions?

Before any licensing negotiation begins, the small biotech must protect its intellectual property during the initial discussions. The NDA signed before sharing compound data is the first contract in the deal process, and it deserves the same legal attention as the license agreement itself. Large pharma companies use their standard NDA templates, which routinely include residuals clauses that allow their scientists to use information retained in memory after the discussions end.

A residuals clause in a pharma NDA is particularly dangerous for small biotech because the information shared during initial discussions often includes compound structures, synthesis routes, and SAR (structure-activity relationship) data. If this information is retained in the memory of the large pharma’s scientists, and the residuals clause permits unrestricted use of such retained information, the small biotech has effectively given the large pharma a non-exclusive license to its most valuable data without any compensation. At Lopes Law LLC, we review and negotiate pharma NDAs for small biotech clients at flat fees, typically completing the review within 48 to 72 hours.

Data room security is another pre-negotiation consideration. Before sharing any compound-specific data with a large pharma, the small biotech should use a secure virtual data room with watermarking, access logging, and download restrictions. The NDA should reference the data room access terms and specify that all data room materials are confidential information subject to the NDA restrictions. Without these protections, it is difficult to prove what information was shared and with whom if a dispute arises later.

Patent portfolio timing also matters before entering major negotiations. If provisional patent applications have not yet been filed on the lead compound and key analogs, they should be filed before any data is shared with a potential licensing partner. An NDA prevents the receiving party from misusing your information, but a patent prevents anyone from practicing the claimed invention regardless of how they learned about it. Both protections work together, and both should be in place before the first technical meeting with a potential partner.

What Timeline Should Small Pharma Expect for Licensing Negotiations?

Licensing negotiations between a small biotech and a large pharma company typically take 6 to 12 months from the initial NDA to the signed license agreement. The process moves through several stages: NDA execution and initial data sharing (2 to 4 weeks), due diligence by the large pharma (4 to 12 weeks), term sheet negotiation (4 to 8 weeks), and full agreement drafting and negotiation (8 to 16 weeks). Each stage has specific legal work requirements that the small biotech should plan for.

The term sheet stage is where the most consequential commercial decisions are made. The upfront payment, milestone structure, royalty rate, territory scope, and diligence framework are all established in the term sheet. Although term sheets are presented as non-binding on these commercial terms, the reality is that it is very difficult to renegotiate a term sheet provision once both parties have agreed to it. The term sheet becomes the baseline from which all subsequent negotiation proceeds. At Lopes Law LLC, we advise small biotech clients to treat the term sheet negotiation with the same rigor they would apply to the final agreement.

Reach out, we are friendly. Call now for a free consultation at (267) 777-9117.

This article is for informational purposes only and does not constitute legal advice. Consult a licensed attorney before making any legal decisions.

Related reading: Pharma Licensing Agreements | Pharmaceutical NDAs | Pharma Confidentiality Agreements